small molecule

AUSTEDO XR

DEUTETRABENAZINE

Loss of exclusivityJune 2041latest FDA-listed patent expiry
CompanyTEVA NEUROSCIENCE INC

Drug detail

Brand nameAUSTEDO XR
Active ingredientDEUTETRABENAZINE
Strength42MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2024
Marketing statusRX

Listed patents

PatentExpiresType
12599598June 2041use U-1995
11311488June 2041product
12589075June 2041use U-1995
11179386*PEDSeptember 2038—
11813232*PEDSeptember 2038—
11813232March 2038product
11179386March 2038product
12016858*PEDSeptember 2036—
11446291*PEDSeptember 2036—
11564917*PEDSeptember 2036—
11648244*PEDSeptember 2036—
10959996*PEDSeptember 2036—
11357772*PEDSeptember 2036—
11564917March 2036use U-1995
11648244March 2036use U-1995
11357772March 2036use U-3055
10959996March 2036use U-3055
12016858March 2036use U-1995
11446291March 2036use U-1995
9550780*PEDMarch 2034—
9550780September 2033substance, product
8524733*PEDOctober 2031—
8524733April 2031substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.